110 related articles for article (PubMed ID: 21284580)
1. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Rizzo M; Corrado E; Patti AM; Rini GB; Mikhailidis DP
Expert Opin Pharmacother; 2011 Mar; 12(4):647-55. PubMed ID: 21284580
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Ikewaki K; Mochizuki K; Iwasaki M; Nishide R; Mochizuki S; Tada N
Metabolism; 2002 Oct; 51(10):1348-54. PubMed ID: 12370857
[TBL] [Abstract][Full Text] [Related]
3. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo.
Nakaya K; Ayaori M; Uto-Kondo H; Hisada T; Ogura M; Yakushiji E; Takiguchi S; Terao Y; Ozasa H; Sasaki M; Komatsu T; Ohsuzu F; Ikewaki K
Atherosclerosis; 2010 Nov; 213(1):135-41. PubMed ID: 20723893
[TBL] [Abstract][Full Text] [Related]
5. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Rizzo M; Christ ER; Rini GB; Spinas GA; Berneis K
Expert Opin Pharmacother; 2008 Sep; 9(13):2295-303. PubMed ID: 18710354
[TBL] [Abstract][Full Text] [Related]
6. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
Pastromas S; Terzi AB; Tousoulis D; Koulouris S
Int J Cardiol; 2008 May; 126(1):3-12. PubMed ID: 17689745
[TBL] [Abstract][Full Text] [Related]
7. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
Elam MB; Heckman J; Crouse JR; Hunninghake DB; Herd JA; Davidson M; Gordon IL; Bortey EB; Forbes WP
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1942-7. PubMed ID: 9848888
[TBL] [Abstract][Full Text] [Related]
8. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Stone WM; Demaerschalk BM; Fowl RJ; Money SR
J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
[TBL] [Abstract][Full Text] [Related]
9. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice.
Takase H; Hashimoto A; Okutsu R; Hirose Y; Ito H; Imaizumi T; Miyakoda G; Mori T
Arzneimittelforschung; 2007; 57(4):185-91. PubMed ID: 17515288
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
11. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
[TBL] [Abstract][Full Text] [Related]
12. Effects of cilostazol on lipid and fatty acid metabolism.
Nakamura N; Osawa H; Yamabe H; Okumura K; Hamazaki T
Clin Exp Med; 2005 Mar; 4(4):170-3. PubMed ID: 15750763
[TBL] [Abstract][Full Text] [Related]
13. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.
Yoshikawa T; Mitani K; Kotosai K; Nozako M; Miyakoda G; Yabuuchi Y
Horm Metab Res; 2008 Jul; 40(7):473-8. PubMed ID: 18404599
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids.
Filippas-Ntekouan S; Tsimihodimos V; Filippatos T; Dimitriou T; Elisaf M
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1113-1121. PubMed ID: 30360662
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
[TBL] [Abstract][Full Text] [Related]
16. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis.
Sohn M; Lim S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473840
[TBL] [Abstract][Full Text] [Related]
17. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
18. Early-onset type 2 diabetes: higher burden of atherogenic apolipoprotein particles during statin treatment.
Song SH; Gray TA
QJM; 2012 Oct; 105(10):973-80. PubMed ID: 22753665
[TBL] [Abstract][Full Text] [Related]
19. 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts.
Fukasawa M; Nishida H; Sato T; Miyazaki M; Nakaya H
J Pharmacol Exp Ther; 2008 Jul; 326(1):100-4. PubMed ID: 18381926
[TBL] [Abstract][Full Text] [Related]
20. Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Manolis AA; Manolis TA; Melita H; Mikhailidis DP; Manolis AS
J Clin Pharmacol; 2022 Mar; 62(3):320-358. PubMed ID: 34671983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
